TNF and psoriatic arthritis: NCT01882439 (OPAL Beyond). This 6-month, randomized, placebo-controlled, double-blind phase 3 trial evaluated the effects of tofacitinib in patients with psoriatic arthritis with a previous inadequate response to a TNF-α inhibitor.